BRIEF-Lilly Exec Says U.S. Zepbound Performance Is Going Very Well

Feb 6 (Reuters) - Eli Lilly and Co LLY.N:

• LILLY EXEC SAYS UPTAKE OF SINGLE-USE ZEPBOUND VIALS INCREASED IN Q4 THROUGH DIRECT TO CONSUMER WEBSITE SALES - CONF CALL

• LILLY EXEC SAYS U.S. ZEPBOUND PERFORMANCE IS GOING VERY WELL

• LILLY EXEC SAYS IN Q4 ZEPBOUND BECAME THE MARKET LEADER IN THE ANTI-OBESITY MARKET AS MEASURED BY NEW PRESCRIPTIONS

• LILLY EXEC SAYS U.S. PRESCRIPTIONS OF ALZHEIMER'S DRUG KISUNLA STEADILY INCREASING SINCE LAUNCH

• LILLY EXEC SAYS CO PLANS TO START SEVERAL TRIALS ASSESSING INCRETINS IN AREAS SUCH AS BRAIN HEALTH, SUBSTANCE USE DISORDERS, PAIN, OTHERS

Further company coverage: LLY.N